Medlab Clinical (ASX:MDC) - Prezzo delle azioni, notizie e analisi

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

MDC Panoramica delle azioni

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia.

Informazioni sull'azienda

MDC analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Revenue is forecast to grow 41.74% per year

Trading at good value compared to peers and industry

Analisi del rischio

Shares are highly illiquid

Earnings are forecast to decline by an average of 44.7% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (A$15M)

+ 1 più rischio

Medlab Clinical Limited Concorrenti

Immuron

ASX:IMC

AU$22.8m

Cynata Therapeutics

ASX:CYP

AU$48.8m

Noxopharm

ASX:NOX

AU$30.7m

AdAlta

ASX:1AD

AU$11.2m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Medlab Clinical
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$6.60
Massimo di 52 settimane	AU$14.94
Minimo di 52 settimane	AU$6.45
Beta	1.1
1Variazione di 1 mese	0%
Variazione a 3 mesi	-4.21%
Variazione di 1 anno	-43.59%
3Variazione a 3 anni	-79.05%
Variazione a 5 anni	-91.85%
Variazione dall'IPO	-78.00%

Notizie e aggiornamenti recenti

Recent updates

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Oct 06

Rendimenti per gli azionisti

	MDC	AU Biotechs	AU Mercato
7D	0%	1.5%	-0.7%
1Y	-43.6%	18.3%	17.1%

Ritorno vs Industria: MDC underperformed the Australian Biotechs industry which returned 11.4% over the past year.

Rendimento vs Mercato: MDC underperformed the Australian Market which returned -1.5% over the past year.

Volatilità dei prezzi

Is MDC's price volatile compared to industry and market?
MDC volatility
MDC Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.3%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.7%

Prezzo delle azioni stabile: MDC has not had significant price volatility in the past 3 months.

Volatilità nel tempo: Insufficient data to determine MDC's volatility change over the past year.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2012	n/a	Sean Hall	www.medlab.co

Medlab Clinical Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Medlab Clinical con la sua capitalizzazione di mercato?
MDC statistiche fondamentali
Capitalizzazione di mercato	AU$15.07m
Guadagni(TTM)	-AU$8.32m
Ricavi(TTM)	AU$1.54m

9.8x

Rapporto P/S

-1.8x

Rapporto P/E

MDC è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
MDC Conto economico (TTM)
Ricavi	AU$1.54m
Costo del fatturato	AU$336.29k
Profitto lordo	AU$1.20m
Altre spese	AU$9.52m
Guadagni	-AU$8.32m

Ultimi guadagni dichiarati

Jun 30, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)	-3.64
Margine lordo	78.11%
Margine di profitto netto	-541.67%
Rapporto debito/patrimonio netto	0%

Come si è comportato MDC nel lungo periodo?

Vedi performance storica e confronto

This company listing is no longer active

MDC Panoramica delle azioni

Premi

Analisi del rischio

Medlab Clinical Limited Concorrenti

ASX:IMC

AU$22.8m

ASX:CYP

AU$48.8m

ASX:NOX

AU$30.7m

ASX:1AD

AU$11.2m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Recent updates

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Less than half of directors are independent

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Full year 2022 earnings: Revenues exceed analyst expectations

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program

Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program

Less than half of directors are independent

Medlab Clinical Ltd Announces Update on NanoCBDTM

Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain

Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites

CFO, Company Secretary & COO has left the company

Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay

Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd

Medlab Clinical Limited Receives Positive Depression Trial Prelim Results

New 90-day high: AU$0.36

Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm

Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years

Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway

Medlab Clinical Limited Announces NanaBis Observational Study Progression Report

New 90-day high: AU$0.26

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research

New 90-day high: AU$0.21

Full year earnings released - AU$0.059 loss per share

Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million.

Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Medlab Clinical Limited Riepilogo dei fondamenti

9.8x

-1.8x

Guadagni e ricavi